Corrector Program
Fabry disease
Hit to LeadActive
Key Facts
About Octant Biotech
Octant Biotech is a private, pre-revenue drug discovery company pioneering a platform-based approach to engineer small molecule drugs against complex cellular mechanisms. Its core technology, the Octant Navigator, integrates Generative Biology (high-throughput cellular sensor engineering), Generative Chemistry (nano-scale automated synthesis), and Generative AI in a rapid design-build-test-learn cycle. The company has built a diversified preclinical pipeline targeting genetic, oncology, metabolism, and immunology diseases, with its most advanced candidate, OCT-980 for retinitis pigmentosa, having initiated a Phase 1a study in healthy volunteers in Q1 2026.
View full company profileOther Fabry disease Drugs
| Drug | Company | Phase |
|---|---|---|
| GMAC for Fabry Disease | CellGenTech | Preclinical |
| JR-171 (lepunafusp alfa) | JCR Pharmaceuticals | Phase 3 |
| Undisclosed Gene Therapy | uniQure | Preclinical |
| Lucerastat | Idorsia | Phase 3 |
| PRX–115 (pegunigalsidase alfa) | Protalix BioTherapeutics | Submitted |
| Isaralgagene civaparvovec (ST-920) | Sangamo Therapeutics | Phase 1/2 |